ArticleFrontiers in endocrinology2025
Shared diagnostic genes and potential mechanisms between intervertebral disc degeneration and diabetes mellitus revealed by integrated transcriptomic analysis and machine learning.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Intervertebral disc degeneration (IDD) and diabetes mellitus (DM) are clinically associated beyond traditional risk factors, yet the shared molecular mechanisms remain unclear. Methods: We integrated transcriptomic data from IDD and DM cohorts, performed differential expression and protein-protein interaction (PPI) network analyses, and applied machine learning to identify shared diagnostic genes. Pathway enrichment, immune infiltration analyses, and experimental qPCR validation were conducted to explore mechanisms and confirm findings. Results: We identified 138 shared differentially expressed genes enriched in immune-related pathways. Seven hub genes, including PRTN3, were identified by Random Forest models. PRTN3 showed consistent upregulation across discovery, validation, and internal cohorts. Pathway and immune analyses revealed strong associations between PRTN3 expression and neutrophil-related processes in both IDD and DM. Experimental validation confirmed PRTN3 upregulation in blood samples from patients with concurrent IDD and DM. Discussion: Our findings suggest that immune-inflammatory mechanisms, particularly involving neutrophils, underlie the comorbidity between IDD and DM. PRTN3 emerges as a promising shared diagnostic biomarker and potential therapeutic target for these conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.